A Dose Escalation Study of HBI-2438 in Patients With Solid Tumors Harboring KRAS G12C Mutation
Status:
Not yet recruiting
Trial end date:
2025-08-01
Target enrollment:
Participant gender:
Summary
A Phase 1 dose escalation study in patients with advanced solid tumors harboring KRAS G12C
mutation to determine the maximum tolerated dose and recommended Phase II dose of HBI-2438
and characterize its pharmacokinetic profile.